Ann J Hessell

List of Publications by Year in Descending Order

37 papers	3,988 citations	19 h-index	37 g-index
37 ext. papers	4,449 ext. citations	12.1 avg, IF	4.62 L-index

#	Paper	IF	Citations
37	Non-neutralizing antibodies targeting the immunogenic regions of HIV-1 envelope reduce mucosal infection and virus burden in humanized mice.. *PLoS Pathogens*, **2022**, 18, e1010183	7.6	2
36	Phagocytosis by an HIV antibody is associated with reduced viremia irrespective of enhanced complement lysis.. *Nature Communications*, **2022**, 13, 662	17.4	0
35	Differential V2-directed antibody responses in non-human primates infected with SHIVs or immunized with diverse HIV vaccines.. *Nature Communications*, **2022**, 13, 903	17.4	0
34	CD4+ T Cells Are Dispensable for Induction of Broad Heterologous HIV Neutralizing Antibodies in Rhesus Macaques. *Frontiers in Immunology*, **2021**, 12, 757811	8.4	
33	Revisiting an IgG Fc Loss-of-Function Experiment: the Role of Complement in HIV Broadly Neutralizing Antibody b12 Activity. *MBio*, **2021**, 12, e0174321	7.8	2
32	Advancing HIV Broadly Neutralizing Antibodies: From Discovery to the Clinic. *Frontiers in Public Health*, **2021**, 9, 690017	6	5
31	Virus Control in Vaccinated Rhesus Macaques Is Associated with Neutralizing and Capturing Antibodies against the SHIV Challenge Virus but Not with V1V2 Vaccine-Induced Anti-V2 Antibodies Alone. *Journal of Immunology*, **2021**, 206, 1266-1283	5.3	3
30	Polyfunctional Tier 2-Neutralizing Antibodies Cloned following HIV-1 Env Macaque Immunization Mirror Native Antibodies in a Human Donor. *Journal of Immunology*, **2021**, 206, 999-1012	5.3	4
29	Efficacy of silk fibroin biomaterial vehicle for in vivo mucosal delivery of Griffithsin and protection against HIV and SHIV infection ex vivo. *Journal of the International AIDS Society*, **2020**, 23, e25628	5.4	5
28	Rapid Induction of Multifunctional Antibodies in Rabbits and Macaques by Clade C HIV-1 CAP257 Envelopes Circulating During Epitope-Specific Neutralization Breadth Development. *Frontiers in Immunology*, **2020**, 11, 984	8.4	6
27	An HIV Vaccine Targeting the V2 Region of the HIV Envelope Induces a Highly Durable Polyfunctional Fc-Mediated Antibody Response in Rhesus Macaques. *Journal of Virology*, **2020**, 94,	6.6	4
26	Single-dose bNAb cocktail or abbreviated ART post-exposure regimens achieve tight SHIV control without adaptive immunity. *Nature Communications*, **2020**, 11, 70	17.4	21
25	Modified Adenovirus Prime-Protein Boost Clade C HIV Vaccine Strategy Results in Reduced Viral DNA in Blood and Tissues Following Tier 2 SHIV Challenge. *Frontiers in Immunology*, **2020**, 11, 626464	8.4	2
24	Antibodies Tip the Balance Towards an HIV Cure. *Trends in Immunology*, **2019**, 40, 375-377	14.4	5
23	Divergent HIV-1-Directed Immune Responses Generated by Systemic and Mucosal Immunization with Replicating Single-Cycle Adenoviruses in Rhesus Macaques. *Journal of Virology*, **2019**, 93,	6.6	7
22	IL-33 enhances the kinetics and quality of the antibody response to a DNA and protein-based HIV-1 Env vaccine. *Vaccine*, **2019**, 37, 2322-2330	4.1	9
21	Multimeric Epitope-Scaffold HIV Vaccines Target V1V2 and Differentially Tune Polyfunctional Antibody Responses. *Cell Reports*, **2019**, 28, 877-895.e6	10.6	21

20	Passive and active antibody studies in primates to inform HIV vaccines. *Expert Review of Vaccines*, **2018**, 17, 127-144	5.2	27
19	Reduced Cell-Associated DNA and Improved Viral Control in Macaques following Passive Transfer of a Single Anti-V2 Monoclonal Antibody and Repeated Simian/Human Immunodeficiency Virus Challenges. *Journal of Virology*, **2018**, 92,	6.6	30
18	Use of broadly neutralizing antibodies for HIV-1 prevention. *Immunological Reviews*, **2017**, 275, 296-312	11.3	101
17	Differential induction of anti-V3 crown antibodies with cradle- and ladle-binding modes in response to HIV-1 envelope vaccination. *Vaccine*, **2017**, 35, 1464-1473	4.1	11
16	Early short-term treatment with neutralizing human monoclonal antibodies halts SHIV infection in infant macaques. *Nature Medicine*, **2016**, 22, 362-8	50.5	134
15	Induction of neutralizing antibodies in rhesus macaques using V3 mimotope peptides. *Vaccine*, **2016**, 34, 2713-21	4.1	12
14	Achieving Potent Autologous Neutralizing Antibody Responses against Tier 2 HIV-1 Viruses by Strategic Selection of Envelope Immunogens. *Journal of Immunology*, **2016**, 196, 3064-78	5.3	42
13	Envelope variants circulating as initial neutralization breadth developed in two HIV-infected subjects stimulate multiclade neutralizing antibodies in rabbits. *Journal of Virology*, **2014**, 88, 12949-67	6.6	29
12	Emergence of broadly neutralizing antibodies and viral coevolution in two subjects during the early stages of infection with human immunodeficiency virus type 1. *Journal of Virology*, **2014**, 88, 12968-81	6.6	44
11	Simplifying the synthesis of SIgA: combination of dIgA and rhSC using affinity chromatography. *Methods*, **2014**, 65, 127-32	4.6	17
10	Neutralizing antibodies and control of HIV: moves and countermoves. *Current HIV/AIDS Reports*, **2012**, 9, 64-72	5.9	19
9	A nonfucosylated variant of the anti-HIV-1 monoclonal antibody b12 has enhanced FcγRIIIa-mediated antiviral activity in vitro but does not improve protection against mucosal SHIV challenge in macaques. *Journal of Virology*, **2012**, 86, 6189-96	6.6	96
8	Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody. *Proceedings of the National Academy of Sciences of the United States of America*, **2011**, 108, 11181-6	11.5	206
7	Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L. *Journal of Virology*, **2010**, 84, 1302-13	6.6	273
6	Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. *PLoS Pathogens*, **2009**, 5, e1000433	7.6	409
5	Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. *Nature Medicine*, **2009**, 15, 951-4	50.5	449
4	Structural definition of a conserved neutralization epitope on HIV-1 gp120. *Nature*, **2007**, 445, 732-7	50.4	657
3	Fc receptor but not complement binding is important in antibody protection against HIV. *Nature*, **2007**, 449, 101-4	50.4	708

2	Inhibition of HIV-1 infectivity and epithelial cell transfer by human monoclonal IgG and IgA antibodies carrying the b12 V region. *Journal of Immunology*, **2007**, 179, 3144-52	5.3	37
1	Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. *Journal of Virology*, **2001**, 75, 8340-7	6.6	591